6 recruiting, 1 unknown. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 6, Unknown 1 |
Follow Nab-paclitaxel: new trials by email Literature Review of Nab-paclitaxel trials Research Report on Nab-paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer Nab-paclitaxel, Tislelizumab, endoscopic intervention - Renal Pelvic Carcinoma, Tislelizumab | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-11-25 | 2025-11-18 |
| Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study neoadjuvant therapy, Surgery, Adjuvant therapy - NSCLC, Tislelizumab | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 34 | 2025-07-25 | 2026-10-13 |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) - Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-17 |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy - Ureteral Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-15 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine - Triple Negative Breast Cancer, Nab-paclitaxel | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 414 | 2019-11-20 | 2025-09-11 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Epirubicin - Breast Cancer, Triple-negative Breast Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 520 | 2019-11-20 | 2025-09-11 |
| Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas S1 or Gemcitabine - Pancreatic Cancer, Nab-paclitaxel | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 132 | 2019-08-01 | 2019-07-08 |
Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Pancreatic Neoplasms (1) · Ureteral Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Breast Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Breast Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Pancreatic Diseases (1) · Ureteral Diseases (1)
130-nm albumin-bound paclitaxel (5) · Carboplatin (2) · tislelizumab (2) · Capecitabine (1) · Chemotherapy, Adjuvant (1) · Epirubicin (1) · Gemcitabine (1) · Neoadjuvant Therapy (1) · S 1 (combination) (1) · Surgical Procedures, Operative (1)
Tianjin Medical University Second Hospital (3) · Hebei Medical University Fourth Hospital (2) · Qilu Hospital of Shandong University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (7)
Cuizhi Geng, M.D. (2) · Hailong Hu, PhD (2) · Zefei Jiang, M.D. (2)